Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 851-859

  Liu, Yingmiao ^a   Tian, Hongyu ^a   Blobe, Gerard C ^a   Theuer, Charles P ^b   Hurwitz, Herbert I ^a   Nixon, Andrew B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Tracon Pharmaceuticals Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GDF2 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; MONOCLONAL ANTIBODY; SMAD PROTEIN; TRC105;

APOPTOSIS; CELL CULTURE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; GROWTH DIFFERENTIATION FACTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; SMAD PROTEINS;

EID: 84925409921     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0129-y     Document Type: Article

References (37)

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249-257
2. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev 6(4):273-286
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
4. Van Meter ME, Kim ES (2010) Bevacizumab: current updates in treatment. Curr Opin Oncol 22(6):586-591. doi:10.1097/CCO.0b013e32833edc0c
5. Jayson GC, Hicklin DJ, Ellis LM (2012) Antiangiogenic therapy-evolving view based on clinical trial results. Nat Rev Clin Oncol 9(5):297-303. doi:10.1038/nrclinonc.2012.8
6. Samant RS, Shevde LA (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2(3):122-134
7. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267(27):19027-19030
8. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1(12):1623-1634
9. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23(20):4018-4028
10. Nolan-Stevaux O, Zhong W, Culp S, Shaffer K, Hoover J, Wickramasinghe D, Ruefli-Brasse A (2012) Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS ONE 7(12):e50920. doi:10.1371/journal.pone.0050920
11. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21(7):1743-1753
12. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14(7):1931-1937
13. Seon BK, Haruta Y, Matsuno F, Haba A, Takahashi N, She X, Harada N, Uneda S, Tsujie M, Tsujie T, Toi H, Tsai H (2010) Receptor-targeted anticancer therapy. Immunol Res 46(1-3):189-191. doi:10.1007/s12026-009-8131-8
14. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 86(1):12-19. doi:10.1093/cvr/cvp332
15. Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y (2011) Endoglin-targeted cancer therapy. Curr Drug Deliv 8(1):135-143
16. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS (2012) A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18(17):4820-4829. doi:10.1158/1078-0432.CCR-12-0098
17. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329-333
18. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK (2008) Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 122(10):2266-2273. doi:10.1002/ijc.23314
19. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Lowik CW, ten Dijke P (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120(Pt 6):964-972. doi:10.1242/jcs.002949
20. Haruta Y, Seon BK (1986) Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci U S A 83(20):7898-7902
21. Senger DR, Van deWater L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12(3-4):303-324
22. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676. doi:10.1038/nm0603-669
23. Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Paez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K (2013) Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 210(3):563-579. doi:10.1084/jem.20120662
24. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, Bernabeu C, Vary CP (2004) Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. J Biol Chem 279(26):27440-27449
25. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S (2000) CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14(1):55-64
26. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P (2003) Activin receptor-like kinase (ALK) 1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12(4):817-828
27. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S (2005) Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39(5):733-742. doi:10.1016/j.yjmcc.2005.07.003
28. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204(2):574-584. doi:10.1002/jcp.20311
29. Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, Round A, Rubio V, Bernabeu C, Marina A (2012) Structural and functional insights into endoglin ligand recognition and binding. PLoS ONE 7(2):e29948. doi:10.1371/journal.pone.0029948
30. Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB (2014) Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med. doi:10.1002/cam4.207
31. Kumar S, Pan CC, Bloodworth JC, Nixon A, Theuer C, Hoyt DG, Lee NY (2013) Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-beta signaling. Oncogene. doi:10.1038/onc.2013.386
32. Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R, Grinberg AV (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286(34):30034-30046. doi:10.1074/jbc.M111.260133
33. Sanz-Rodriguez F, Guerrero-Esteo M, Botella LM, Banville D, Vary CP, Bernabeu C (2004) Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J Biol Chem 279(31):32858-32868. doi:10. 1074/jbc.M400843200
34. Lee NY, Blobe GC (2007) The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem 282(29):21507-21517. doi:10.1074/jbc.M700176200
35. Lee NY, Ray B, How T, Blobe GC (2008) Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 283(47):32527-32533. doi:10.1074/jbc.M803059200
36. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320(2):130-137. doi:10.1016/j.canlet.2012.03.008
37. Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13(1-2):16-28. doi:10.1016/j.drup.2009.12.001